R

REGENXBIO
D

RGNX

7.28000
USD
-0.09
(-1.15%)
مغلق
حجم التداول
12,713
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
360,688,117
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ALNY
    ALNY
    -0.480
    (-0.19%)
    250.450 USD
    B
    BLUE
    -2.93000
    (-41.68%)
    4.10000 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    N
    NTLA
    -0.075
    (-0.61%)
    12.180 USD
    Q
    QURE
    -0.130
    (-1.00%)
    12.840 USD
    R
    RARE
    -1.920
    (-4.31%)
    42.590 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    S
    SRPT
    -2.010
    (-1.86%)
    106.280 USD
    VRTX
    VRTX
    4.10
    (0.85%)
    484.53 USD
    المزيد
الأخبار
المقالات

العنوان: REGENXBIO

القطاع: Healthcare
الصناعة: Biotechnology
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.